| 000 | 01759 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517231412.0 | ||
| 264 | 0 | _c20190812 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/key188 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKurasawa, Kazuhiro | |
| 245 | 0 | 0 |
_aTofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _c12 2018 |
||
| 300 |
_a2114-2119 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aDermatomyositis _xblood |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFerritins _xblood |
| 650 | 0 | 4 |
_aGlucocorticoids _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-Induced Helicase, IFIH1 _xblood |
| 650 | 0 | 4 |
_aLung _xpathology |
| 650 | 0 | 4 |
_aLung Diseases, Interstitial _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPiperidines _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrroles _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aArai, Satoko | |
| 700 | 1 | _aNamiki, Yumeko | |
| 700 | 1 | _aTanaka, Ayae | |
| 700 | 1 | _aTakamura, Yuta | |
| 700 | 1 | _aOwada, Takayoshi | |
| 700 | 1 | _aArima, Masafumi | |
| 700 | 1 | _aMaezawa, Reika | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 57 _gno. 12 _gp. 2114-2119 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/key188 _zAvailable from publisher's website |
| 999 |
_c28683251 _d28683251 |
||